论文部分内容阅读
目的观察甘精胰岛素治疗2型糖尿病(T2DM)患者的临床疗效及安全性。方法观察58例T2DM患者治疗前和采用二甲双胍缓释片联合甘精胰岛素治疗10周后空腹血糖(FPG)、餐后2 h血糖(2 h PG)及糖化血红蛋白(HbA1c),水平观察治疗期间低血糖发生情况。结果两组FPG、2 h PG、HbA1c均降低,组间比较差异均无统计学意义(P>0.06),治疗后和治疗前低血糖发生率分别为6.90%、22.41%(P<0.01)。结论甘精胰岛素联合二甲双胍缓释片治疗T2DM安全有效。
Objective To observe the clinical efficacy and safety of insulin glargine in patients with type 2 diabetes mellitus (T2DM). Methods Fasting plasma glucose (FPG), 2 h postprandial plasma glucose (2 h PG) and HbA1c were measured in 58 patients with T2DM before treatment and after metformin treatment with metformin for 10 weeks. The levels of HbA1c, Blood sugar situation. Results The FPG, 2 h PG and HbA1c in both groups were decreased. There was no significant difference between the two groups (P> 0.06). The incidence of hypoglycemia after treatment and before treatment were 6.90% and 22.41%, respectively (P <0.01). Conclusion Glargine and metformin sustained-release tablets in the treatment of T2DM are safe and effective.